CClinicalTrials.gg
CompletedNCT03758183Updated Nov 29, 2018

Cost Effectiveness of Prolotherapy Injections Prior to Total Knee Arthroplasty

An observational study in Knee Osteoarthritis, sponsored by Tokat State Hospital. Completed at 1 site in Turkey. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-11-29.

Sponsored by Tokat State Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
197
Ages
50 Years to 70 Years
Sex
All
01

Study summary

This study compared the cost effectiveness of two-stage algorithm (prolotherapy injections (PrT) combined with rehabilitation protocol (RP) prior to total knee arthroplasty (TKA)) and one-stage algorithm (TKA) in the management of advanced stage knee osteoarthritis.

Read the detailed description

The aim of the present study was to compare the cost effectiveness of two-stage algorithm (prolotherapy injections (PrT) combined with rehabilitation protocol (RP) prior to total knee arthroplasty (TKA)) and one-stage algorithm (TKA) in the management of advanced stage knee osteoarthritis.

A total of 197 patients who had chronic knee osteoarthritis were included in the present study. The patients were divided into two groups as two-stage algorithm (PrT combined with RP prior to TKA), (Group A, n=98) and one-stage (TKA),(Group B, n=99). Clinical effectiveness was evaluated via Visual Analog Scale (VAS), The Western Ontario and McMaster Universities Arthritis Index (WOMAC) at baseline and 3-, 6-, 12-, and 18-month follow-ups. Utility scores of the groups were obtained by extracting and converting WOMAC scores to health utilities index mark 3 scores. Cost-utility per quality-adjusted life years (QALY) and Incremental cost-effectiveness ratios (ICERs) of each group were calculated.

02

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Arthroplasty
  • Prolotherapy
  • Osteoarthritis
03

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's enrollment of 197 is above the median of 100 across 791 observational studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

This is the only study on the registry with Tokat State Hospital as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Age of the patients varied between 50 and 90

Inclusion criteria

  • III and IV levels of knee osteoarthritis according to Kellgren-Lawrence
  • Had at least six months of symptoms resistant to at least three months of conservative methods (lifestyle modification, weight reduction, regular exercise, physiotherapy, non-steroidal anti-inflammatory drugs, intraarticular injection methods) -

Exclusion criteria

Exclusion Criteria:

  • With rheumatic diseases, immune diseases or other systemic inflammatory diseases
  • With active infection, osteomyelitis or history of chronic infection around knee joint
  • Had undergone previous operation on knee
  • Had bleeding tendency (hereditary or acquired)
  • Pregnant patients
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
197 participants (actual)
Patient registry
No

Groups and cohorts

  • two-stage algorithm

    Prolotherapy injections (PrT) combined with rehabilitation protocol (RP) prior to total knee arthroplasty (TKA)

    Procedure: total knee arthroplasty

  • one-stage algorithm

    total knee arthroplasty (TKA)

    Procedure: total knee arthroplasty

Interventions

  • Proceduretotal knee arthroplasty

    Also known as: injection, prolotherapy

06

What researchers measure

Primary outcomes

  1. Visual Analog Scale (VAS)

    Self reported pain intensity. Each item is scored 0-10 (0=no pain; 10= pain as bad as can be), yielding a total between 0 and 10.

    Time frame: 18 months

  2. The Western Ontario and McMaster Universities Arthritis Index (WOMAC)

    Self-administered questionnaire consisting of 24 items divided into 3 subscales: Pain (5 items): during walking, using stairs, in bed, sitting or lying, and standing upright Stiffness (2 items): after first waking and later in the day Physical Function (17 items): using stairs, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy domestic duties, light domestic duties. Each item is scored 0-96 (0=minimum; 96= as bad as can be), yielding a total between 0 and 96.

    Time frame: 18 months

07

Study locations

1 site
  • Serkan Akpancar
    Tokat, 60060, Turkey
08

References and documents

Individual participant data

Plan to share: Yes — All primary and secondary data will be made available.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03758183
Lead sponsor
Tokat State Hospital
Responsible party
Serkan Akpancar (Dr, Tokat State Hospital) — Principal investigator
First posted
Nov 29, 2018
Start date
Jan 1, 2016
Primary completion
Jan 1, 2017
Completion
Oct 24, 2018
Last update
Nov 29, 2018

Study contacts

Serkan Akpancar, Dr
study director · Tokat State Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion